Orbis Medicines, a leader in the discovery of next-generation macrocycles, oral medicines with biologics-like potency, today announced the appointment of Joanne Smith-Farrell, Ph.D., as Chief Executive Officer. She succeeds co-founder Morten Graugaard, who becomes Chief Business Officer.
Dr. Smith-Farrell will lead Orbis as it evolves its platform and advances its wholly owned immunol-ogy and inflammation programs and partnered portfolio. The portfolio includes a multi-target car-diometabolic collaboration with Novo Nordisk worth up to $1.4 billion. Mr. Graugaard will focus on business development and strategic partnerships, building on his role in establishing the Novo Nordisk collaboration.
